Reckoner BBB-B CLO Annual ETF
RCLY · ETF
About RCLY
- Issuer
- Reckoner
- Expense ratio
- 0.55%
- Assets under management
- $18.05M
- Inception
- Feb 11, 2026
- Asset class
- Fixed Income
- Website
- www.reckoner.com/RCLY
RCLY key statistics
- Price-earnings ratio
- 0.00
- Average volume
- 49
- Volume
- 6
- Open price
- $102.95
- High today
- $102.95
- Low today
- $102.95
- 52 Week high
- $103.34
- 52 Week low
- $99.48
Reckoner BBB-B CLO Annual ETF (RCLY) at a glance
As of Oct 23, 2026, Reckoner BBB-B CLO Annual ETF (RCLY) shares are priced at $102.95, giving the company a price-to-earnings ratio of 0.00.
Volume so far is 6 shares, below the average of 49 shares a day.
Over the past year Reckoner BBB-B CLO Annual ETF has ranged from $99.48 to $103.34, and now sits 90% of the way up that range.
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- GTVHGolden Triangle Ventures$0.0002+100.00%
- TMSHTrans Global Assets$0.0003+20.00%
- RDARRaadr$0.0002+0.00%
- GPUSHyperscale Data$0.1689+34.05%
- SEIISharing Economy International$0.0002−33.33%
- ELMEElme Communities$1.77+0.57%
- SHFSSHF Holdings$0.1324−61.39%
- XXII22nd Century Group$0.1977−8.34%
- NBNDNetBrands$0.0006−40.00%
- NVDGraniteShares ETF Trust$4.19+0.96%
- HIRUHiru$0.0006+9.09%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.49−0.10%
- CTYCITY THERAPEUTICS$20.77+0.00%
- IAMIambic Therapeutics$14.26−2.79%
- AMROAmaero$5.84+7.75%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.30+0.29%
- TRXBTRex Bio$13.81−10.90%
- RTSNRetension Pharmaceuticals$15.25−1.61%
- PAXGUPine Tree Acquisition$10.01+0.05%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.13−0.77%
- ACCVAccelevation Holdings$12.38+1.06%
- RZAIROZE AI$10.92−1.89%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.